Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone.
Alberto Ortiz ArduanRoberto Alcázar ArroyoPedro Pablo Casado EscribanoBeatriz Fernández-FernándezFrancisco Martínez DebénJuan Diego MediavillaAlfredo Michán-DoñaMaria Jose SolerJose Luis Gorriz TeruelPublished in: Expert review of clinical pharmacology (2023)
As finerenone increases potassium levels in a predictable way, patients at risk of hyperkalemia can be identified early in clinical practice and monitored for an easy management. This will allow people with T2DM and CKD to safely benefit from improved cardiorenal outcomes.